Fortress Biotech Inc expected to post a loss of 59 cents a share - Earnings Preview

Fortress Biotech

08/11/2024 15:51

* Fortress Biotech Inc  FBIO.OQ   FBIO.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
12 (estimated) for the period ending January 1 0001
    * The Bay Harbor Islands Florida-based  company is expected
to
report a 7.3% decrease in revenue to $32.218 million from $34.75
million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Fortress Biotech Inc is
for a
loss of 59 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fortress
Biotech
Inc is 13.00​, above​ its last closing price of $1.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.14       -1.22      -0.73     Beat    40.3
 Mar. 31 0001  -1.69       -1.73      -1.03     Beat    40.5
 Dec. 31 2023  -1.67       -1.97      -1.28     Beat    34.9​
 Sep. 30 2023  -3.12       -3.21      -0.94     Beat    70.7
 ​​Jun.        -3.31       -3.41      -3.60     Missed  -5.5
 30 2023                                                
 Jan. 1 0001   -3.38       -3.00      -3.15     Missed  -5​
 Jan. 1 0001   -3.43       -3.37      -4.46     Missed  -32.2
 Sep. 30 2022  -3.18       -4.05      -3.75     Beat    7.4
 This summary was machine generated November 8 at 15:50 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)